DIRS.INFO The most relevant business & tech news

☆ 30 essential tips for living a longer, happier, more successful life with no regrets
▼ + stars: | 2024-10-31 | by ( Aditi Shrikant | ) www.cnbc.com time to read: +6 min

The anti-aging market is littered with innovative products and procedures that promise consumers a healthier, happier, longer life. But prolonging your life isn't only about physical fitness: a near 90-year-long study from Harvard University found that those who live happier, longer lives have good relationships. If you want to live longer and feel more fulfilled you probably don't need lasers or freezers. 30 essential tips for living a longer, happier, more successful life1. If you can't drive, don't live somewhere where the doctor is a 30-minute car ride away.

Persons: superagers, dieticians, Warren, Buffets, Valter Longo, David Watson, Warren Buffet, Neil Paulvin, Danielle Miura, Mark La Spisa, García, Francesc Miralles, Charlie, Munger, Warren Buffett, it's, Thema Bryant Organizations: Harvard University, Italy —, Cancer Laboratory, IFOM, of Oncology, University of Notre Dame, GameStop Locations: New York City, Blue, Okinawa, Japan, Sardinia, Italy

☆ New cervical cancer treatment cuts risk of death from disease, according to trial results
▼ + stars: | 2024-10-16 | by ( Sam Tupper | ) edition.cnn.com time to read: +5 min

All had locally advanced cervical cancer, although none had tumors that had spread to other organs. This discovery led to the development of an HPV vaccine that can help prevent cervical cancer in women. Brawley stressed the importance of routine cervical screening as advanced-stage cervical cancer rises among White and Black women in the US. According to the US Centers for Disease Control and Prevention, cervical cancer screenings typically test for signs of HPV that can cause cell changes on the cervix. “Of the 4,400 deaths from cervical cancer, none of them get screened every year.”Chemotherapy to treat cervical cancer can come with unpleasant side effects like nausea, vomiting and hair loss, Brawley noted.

Persons: ” Dr, Mary McCormack, “, ”, Otis Brawley, Harald zur Hausen, Brawley, White, Dr, Sanjay Gupta, It’s, ” Brawley, “ We’re Organizations: CNN, Mary McCormack of University College Hospital, Cancer Research, Johns Hopkins University, American Cancer Society, US Centers for Disease Control, CNN Health, US Food and Drug Administration Locations: Brazil, India, Italy, Mexico, United States

☆ Stocks making the biggest moves midday: ASML, UnitedHealth, Walgreens Boots Alliance and more
▼ + stars: | 2024-10-15 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Check out the companies making headlines in midday trading: UnitedHealth — Shares plunged 7.2% after the health-care giant lowered its earnings guidance due to ongoing headwinds from a cyberattack earlier in the year. Walgreens Boots Alliance — The stock soared 11.9% following the drugstore chain's fiscal fourth-quarter earnings and revenue beat. Enphase Energy — Shares slid 6.8% on the back of a downgrade to sector perform from outperform by RBC Capital Markets. Johnson & Johnson — The health-care conglomerate gained 1.6% after posting quarterly results that exceeded expectations on the back of strong sales of oncology drugs. Energy stocks — Energy stocks declined as oil prices dropped about 5% , with the sector last down more than 2%.

Persons: UnitedHealth, ASML, Johnson, LSEG, Halliburton, Coty, Charles Schwab —, Yun Li, Alex Harring, Hakyung Kim, Michelle Fox, Pia Singh, Sarah Min Organizations: Walgreens, Alliance, Nvidia, Devices, Broadcom, Apollo, Bank of America, Enphase Energy, RBC Capital Markets, Energy, — Energy, APA, Diamondback Energy, Occidental Petroleum, Valero Energy, U.S, Citigroup —, PNC Financial, Boeing Locations: North Carolina, New York, Pittsburgh

☆ Stocks making the biggest moves premarket: Goldman Sachs, Bank of America, Walgreens and more
▼ + stars: | 2024-10-15 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +3 min

Bank of America -- Shares moved 1% higher after third-quarter earnings and revenue topped Wall Street analysts' estimates. Goldman Sachs — Shares of the investment bank jumped more than 2% on better-than-expected quarterly earnings. Goldman Sachs posted earnings per share of $8.40 on $12.70 billion in revenue. Citigroup — Shares of the Jane Fraser-led bank added 1.7% after third-quarter earnings and revenue were better than consensus estimates. Charles Schwab — The brokerage company surged more than 7% after third quarter results beat analysts' estimates.

Persons: Johnson, J, Goldman Sachs, LSEG, UnitedHealth, Walgreens, Jane Fraser, Coty –, Coty, Charles Schwab, —, Yun Li, Michelle Fox, Samantha Subin, Sarah Min, Pia Singh Organizations: Bank of America, Wall, LSEG, Revenue, Johnson, Walgreens, Alliance, Citigroup —, Citigroup, PNC Financial, PNC, Coty, Energy, RBC Capital Markets, EV Locations: Pittsburgh, LSEG .

☆ Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
▼ + stars: | 2024-09-16 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +9 min

watch nowDrugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. That can allow the treatment to deliver radiation to cancer cells and spare the rest of the body from the level of damage that comes with many cancer drugs. For Pluvicto, patients come in once every six weeks for up to six treatments. One opportunity Bristol Myers Squibb sees is combining radiopharmaceuticals with existing cancer drugs like immunotherapy, said Robert Plenge, Bristol's chief research officer. But she thinks the technology will become an important part of cancer drugs in the next decade.

Persons: Eli Lilly, They've, Michael Schmidt, Schmidt, Franco Origlia, Jacob Van Naarden, Eli Lilly's, Lilly, Biopharma, Van Naarden, Radiopharmaceuticals, Bristol Myers, Ben Hickey, RayzeBio, Hickey, Victor Bulto, Bulto, Timothy Korytko, Ronald Coy, Sharon, Ronald Coy Ronald Coy, Coy, who's, Coy hasn't, she's, we've, Eli Lilly's Van Naarden, Bristol Myers Squibb, Robert Plenge, Susan Galbraith, Galbraith Organizations: Bristol Myers Squibb, AstraZeneca, Guggenheim Securities, Novartis, NSA, Pharmaceutical, Bassett Healthcare Network, Bristol, Fusion Pharmaceuticals, Guggenheim Locations: Aedea Rome, Italy, radiopharmaceuticals, Swiss, FactSet, Bristol, Indiana, U.S, New York, Bassett

☆ A promising cancer treatment is poised for explosive growth, says Redburn Atlantic. These stocks are on its buy list
▼ + stars: | 2024-09-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The latest weapon in the battle against cancer is showing promising results — and it's a growing opportunity for investors, according to Redburn Atlantic. To treat cancer, targeted radiopharmaceutical therapy directly goes after tumors with radiation by binding a radioactive particle to a targeting molecule. Delving into diagnostics There are also opportunities in the radiopharma diagnostics space, according to Redburn Atlantic. It has a "strong pipeline of radionuclides for both diagnosis and therapy," he said. "Lantheus benefits from its focus on this rapidly expanding market, with 78% of revenues from radiopharmaceuticals and related products," Ridley-Day added.

Persons: Ed Ridley, Eli Lilly, Myers, Ridley, Astra's, Lantheus Organizations: Big pharma, Novartis, Mariana Oncology, Biopharma, Myers Squibb, RayzeBio, AstraZeneca, Fusion Pharmaceuticals, GE Healthcare Technologies, Lantheus Holdings, GE Healthcare, GE Locations: Bristol, radiopharmaceuticals

☆ Gen X, millennials face higher risk of 17 cancers than older generations
▼ + stars: | 2024-07-31 | by ( Kaitlin Sullivan | Kaitlin Sullivan Is A Contributor For Nbcnews.Com Who Has Worked With Nbc News Investigations. She Reports On Health | Science | ) www.nbcnews.com time to read: +5 min

The risk was two to three times higher in people born in 1990 for pancreatic, kidney and small intestine cancers, compared to people born in 1955. Liver cancer diagnoses in women followed the same pattern. About 20% of cancer diagnoses in the U.S. are linked to excess body weight, according to the American Cancer Society. Obesity rates in the nation changed little in the 1960s and 1970s but increased sharply after that. Among children, obesity rates grew from 5% to 17% in the same period.

Persons: Sung, —, ”, Andrea Cercek, ” Brawley, Otis Brawley, it’s, ” Cercek Organizations: North American Association of Central Cancer, U.S . National Center for Health Statistics –, Memorial Sloan Kettering Cancer Center, “, Bloomberg, Oncology, Epidemiology Johns Hopkins University, American Cancer Society, Centers for Disease Control Locations: U.S

☆ AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
▼ + stars: | 2024-03-19 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomesDr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.

Persons: Susan Galbraith Organizations: AstraZeneca, Fusion, Fusion Pharmaceuticals

☆ Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors
▼ + stars: | 2024-03-13 | by ( Brenda Goodman | ) edition.cnn.com time to read: +10 min

Only 3% to 5% of people who are diagnosed with this type of brain tumor will be alive three years later. Now, an experimental therapy that reprograms a person’s own immune cells to attack these tumors is showing some exciting promise. Doctors first harvested immune fighters called T-cells from his blood and then genetically modified them in a lab so they’d recognize and bind to specific proteins on the surface of the brain tumor cells. After a single 10-milliliter infusion of about 10 million CAR-T cells, Fraser’s tumor began to shrink. Three-quarters of the participants had had their brain tumors come back at least twice.

Persons: ”, Otis Brawley, –, they’ll, ” Brawley, Tom Fraser, Brigham, Debbie Fraser, Fraser, He’s, Marcela Maus, ” Fraser, Maus, “, ” Maus, Christine Brown, ’ Brown, ” Brown, hasn’t, Brown, Dr, Donald O’Rourke, “ They’re, O’Rourke, ” O’Rourke, Sanjay Gupta, you’re, they’re, it’s Organizations: CNN, Johns Hopkins University, American Cancer Society, City of Hope Cancer Center, University of Pennsylvania, Massachusetts General, Mass, New England, of Medicine, Doctors, Mass General Cancer Center, Tv3, Cell Therapeutics Research, of, Nature, Penn, Excellence, University of Pennsylvania Perlman School of Medicine, CNN Health Locations: City, Duarte , California, Massachusetts, Rochester , New York, Boston, of Hope, Hope

☆ This risk assessment tool helped Olivia Munn discover her breast cancer
▼ + stars: | 2024-03-13 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +10 min

The “X-Men: Apocalypse” star, 43, wrote in an Instagram post Wednesday that she was diagnosed with breast cancer last year and would not have discovered it if her physician, Dr. Thaïs Aliabadi, had not calculated her breast cancer risk score. A breast cancer risk assessment tool uses a statistical model to estimate a woman’s risk of developing breast cancer over the next five years as well as over her lifetime, or up to about age 90, according to the National Cancer Institute. Two models are commonly used as breast cancer risk assessment tools: the Gail Model and the Tyrer-Cuzick Risk Assessment Calculator. An online version of the breast cancer risk assessment tool, using the Gail Model, is available for anyone to take at bcrisktool.cancer.gov. In fact, some women who do not develop breast cancer have higher risk estimates than some women who do develop breast cancer,” according to the National Cancer Institute’s website.

Persons: Olivia Munn’s, Thaïs Aliabadi, Aliabadi, Munn, Gail, Jennifer Plichta, “, ” Plichta, they’re, ”, Plichta, I’ve, they’ve, Otis Brawley, ” Brawley, Larry Norton, Evelyn H, ” Norton, Robert Smith, Ruth Oratz, NYU Langone Health’s, Dr, Sanjay Gupta, ” Oratz Organizations: CNN, National Cancer Institute, National Cancer, Duke Cancer Institute, Johns Hopkins University, Lauder Breast Center, Memorial Sloan Kettering Cancer Center, American Cancer Society, US Preventive Services Task Force, NYU, Cancer Center, NYU Grossman School of Medicine, CNN Health Locations: United States, Durham , North Carolina

☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
▼ + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +13 min

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.

Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California

☆ Smoking’s effects on the immune system can last years, study finds
▼ + stars: | 2024-02-14 | by ( Jen Christensen | ) edition.cnn.com time to read: +5 min

They exposed the blood samples to common germs like E. coli bacteria and the flu virus and measured the immune response. It had nearly the same impact on immune response as important factors such as age or sex. The innate immune response is the general way the skin, mucous membranes, immune system cells and proteins fights germs. The experiment was done in blood samples in the lab, but the immune system may react differently in real life. Those mice cleared a bacterial infection less efficiently and with a less-robust immune response than mice that weren’t exposed.

Persons: they’ve, it’s, ”, Dr, Violaine, “, André, Darragh Duffy, “ It’s, ” Duffy, Duffy, Yasmin Thanavala, There’s, ” Thanavala, Sanjay Gupta, Albert Rizzo, we’ve, Rizzo Organizations: CNN, Nature, Institut Pasteur, Immunology, Roswell, Cancer Institute, Get CNN, CNN Health, American Medical Association Locations: United States, Paris

☆ More young people are dying of colorectal cancer. Three lifestyle factors could be partly to blame, scientists say.
▼ + stars: | 2024-02-02 | by ( Kim Schewitz | ) www.businessinsider.com time to read: +5 min

Colorectal cancer deaths among younger people in Europe are forecast to rise by around a third in 2024.to rise by around a third in 2024. Obesity, low levels of physical activity, and alcohol might be partly to blame, scientists say. Cancer researchers from the University of Milan, Italy, predicted that colorectal cancer deaths among people aged 25 to 49 will rise significantly in the EU and the UK this year compared to 2018. AdvertisementAlthough they estimated that deaths from colorectal cancer will fall overall in 2024, this is the first year they have predicted a rise in colorectal cancer deaths among younger people. More people drinking alcohol, which has been linked to early-onset colorectal cancer, and less physical activity could also be factors, the study said.

Persons: —, Christina Annunziata, Chadwick Boseman's, Annunziata, Carlo La Vecchia, La Vecchia, Kimmie Ng Organizations: EU, Service, Cancer, University of Milan, American Cancer Society, Oncology, World Health Organization, Dana, Farber Cancer Institute, NBC Locations: Europe, Italy, Germany, Spain, Poland, France, Boston

☆ One in six Black men will be diagnosed with prostate cancer in their lifetime. Early detection is key to saving lives
▼ + stars: | 2024-01-26 | by ( Nicquel Terry Ellis | ) edition.cnn.com time to read: +5 min

“That was really scary to hear.”One in six Black men will develop prostate cancer in their lifetime, according to the advocacy organization ZERO Prostate Cancer. The rate of prostate cancer among Black men has been underscored in recent weeks as Dexter King, the youngest son of the Rev. And in December, US Defense Secretary Lloyd Austin underwent a prostatectomy to treat prostate cancer that was discovered that same month. Bugler said ZERO Prostate Cancer recommends that Black men start talking to their doctors about the risks and benefits of prostate cancer screening at the age of 40. He blames toxic masculinity and stubbornness, which he said can also play a role in preventing Black men from getting screened for prostate cancer.

Persons: Nate Battle, doctor’s, “, ‘, ”, Dexter King, Martin Luther King Jr, Lloyd Austin, aren’t, it’s, Otis Brawley, ” Brawley, Brawley, Johns Hopkins, ” Courtney Bugler, Bugler Organizations: CNN, Prostate Cancer, Research, American Cancer Society, US, Johns Hopkins University, Baltimore and, ZERO Prostate, Cancer Locations: Black, barbershops, Baltimore, Baltimore and Washington

☆ Breast cancer signs you need to look out for
▼ + stars: | 2023-10-16 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +4 min

CNN —Do you know what to look for to detect breast cancer early? “Many breast changes are the result of aging and childbirth; however, breast cancer can present in a number of ways. “The only breast cancers that are cured … are breast cancers that are detected early,” he said. When it comes to breast cancer, men also need that empowerment, Pariser said. “Although the disease is less common in men, 1% of breast cancers occur in men,” she said.

Persons: Arthur G, Richard J, James, Ashley Pariser, – James, Pariser, ”, “, ” Pariser, Otis Brawley, Brawley, don’t, ’ Organizations: CNN, The Ohio State University Comprehensive Cancer, James Cancer Hospital, Solove Research, American Cancer Society, Bloomberg, Johns Hopkins University, Empowerment Locations: United States

☆ Here’s why this under-the-radar biopharma stock could leap nearly 140%, Goldman Sachs says
▼ + stars: | 2023-10-11 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

An overly negative reception to clinical results could mean investors are missing out on potential upside for Syndax Pharmaceuticals , according to Goldman Sachs. The investment bank initiated coverage of the biopharmaceutical company on Wednesday with a buy rating, setting a 12-month price target of $30. This implies potential upside of 137% from the stock's Tuesday closing price of $12.65. In its Oct. 2 announcement, Syndax said it had "positive topline data" from the protocol-defined pooled analysis of this trial. "Based on our analysis and view, we believe the stock is currently trading below the value of near-term commercial opportunities ex-cash/-terminal value," he wrote.

Persons: Goldman Sachs, Syndax, Chris Shibutani, Shibutani, — CNBC's Michael Bloom Organizations: Syndax Pharmaceuticals Locations: 2024E

☆ AstraZeneca succession sickness demands urgent fix
▼ + stars: | 2023-09-15 | by ( Aimee Donnellan | ) www.reuters.com time to read: +3 min

LONDON, Sept 15 (Reuters Breakingviews) - Can a CEO be worth $9 billion? That’s the question posed by the 4% fall in AstraZeneca’s (AZN.L) shares following an article stating boss Pascal Soriot may soon resign. The company has played down the report, and its stock has recovered, but the episode highlights its uncertain position were 64-year-old Soriot to leave. Without a clear succession plan, investors should prepare for further swings. Small wonder investors and analysts wonder whether AstraZeneca will be able to find a successor capable of replicating his success.

Persons: Pascal Soriot, AstraZeneca’s, Ivan Menezes, Debra Crew, Soriot, Susan Galbraith, David Fredrickson, Luke Miels, Soriot’s, Neil Unmack, Streisand Neto Organizations: Reuters, Pfizer, pharma, Novartis, Sanofi, GSK, AstraZeneca, Diageo, Thomson Locations: AstraZeneca’s, Swedish

☆ Cancer diagnosis rates are going up in younger adults, study finds, driven largely by rises in women and people in their 30s
▼ + stars: | 2023-08-16 | by ( Brenda Goodman | ) edition.cnn.com time to read: +4 min

The study found that overall, early-onset cancers increased over that decade, by an average of 0.28% each year. There were 34,233 early-onset cancer cases in women in 2010 and 35,721 in 2019, an increase of 4.35%, the study says. The rate of cancer diagnosis increased in adults in their 30s over the decade but remained stable in other under-50 age groups, the study found. Cancers with the highest numbers of early-onset cases diagnosed in 2019 were breast (12,649 cases), thyroid (5,869) and colorectal cancers (4,097). Previous research has shown a rise in cancers of the digestive system, particularly colorectal cancers, among adults younger than 55 since the 1990s.

Persons: Otis Brawley, Dr, Sanjay Gupta, ”, “, “ There’s, Brawley, John Bonifield Organizations: CNN, National Cancer Institute, JAMA, Bloomberg, Oncology, Johns Hopkins University, CNN Health Locations: Alaska Natives, Black, United States

SummaryCompanies Plans to file trial data with FDAComments sooth some investor concernsAbsence of "clinically meaningful" in interim trial data worried investorsLONDON, July 28 (Reuters) - AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as "clinically meaningful". The drugmaker's (AZN.L) shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media on Friday after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further. The company said on Friday it will continue with its plan to file data from the trial with the U.S. Food and Drug Administration (FDA), soothing some investor concerns. In a briefing with analysts, Susan Galbraith, executive vice president of oncology R&D, said the FDA response to the data so far had been "encouraging".

Persons: Pascal Soriot, Soriot, Susan Galbraith, Maggie Fick, Josephine Mason, David Evans, Susan Fenton Organizations: LONDON, AstraZeneca, U.S . Food, Drug Administration, FDA, U.S, Thomson

Reuters reported last month that the cancer research arm of the World Health Organization (WHO), known as the International Agency for Research on Cancer (IARC), was set to make that declaration on July 14, according to two sources with knowledge of the process. The designation as "possibly carcinogenic to humans" will provide an incentive to fund more rigorous research into the safety question, toxicology and cancer experts say. "We have been pushing for an IARC review for many years now." But no action was taken until 2022, after aspartame was again nominated for review by CSPI and Melnick in 2019. The research body has said "new evidence" prompted its aspartame review, without giving any details.

Persons: Andy Smith, Smith, Coke, Peter Lurie, Lurie, James Huff, Ron Melnick, CSPI, There's, Samuel Cohen, Erik Millstone, Millstone, Jennifer Rigby, Michele Gershberg, Catherine Evans Organizations: Reuters, World Health Organization, WHO, International Agency for Research, Cancer, MRC, Unit, University of Cambridge, Cola's, Regulators, for Science, Joint Food and Agriculture Organization, U.S . National Institutes of Health, University of Nebraska Medical Center, University of Paris, Britain's University of Sussex, Thomson Locations: United States, U.S, France

☆ AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
▼ + stars: | 2023-06-04 | by ( Natalie Grover | ) www.reuters.com time to read: +2 min

LONDON, June 4 (Reuters) - AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed. The drug has regulatory approvals across multiple geographies for certain patients with so-called non small cell lung cancer (NSCLC) who have a mutation of the EGFR gene. In the trial, Tagrisso or a placebo was given to patients to assess whether the AstraZeneca therapy could keep their cancer at bay. An estimated 88% of patients treated with Tagrisso were alive at five years compared to 78% on placebo, trial data also showed. AstraZeneca is also expecting to provide details on the impact of combining Tagrisso with chemotherapy in patients with advanced EGFR-mutated lung cancer later this year.

Persons: Tagrisso, Susan Galbraith, Dave Fredrickson, Natalie Grover, Angus MacSwan Organizations: American Society of Clinical Oncology, AstraZeneca, Reuters, Thomson Locations: Swedish, London

☆ Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
▼ + stars: | 2023-06-02 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. Kisqali has been approved to treat hormone-driven breast cancer that has spread to other parts of the body, where Novartis has taken market share from Pfizer's (PFE.N) Ibrance. But that is in a subset of women who are at high risk of recurrence after surgery, typically diagnosed based on signs of cancer in the lymph nodes. Here, Novartis will face tough competition because the U.S. drugmaker has said Verzenio reduces the risk of recurrence by 35% in that group. Novartis will request approval for wider use in the U.S. and Europe before the end of the year, it added.

Persons: Kisqali, Eli Lilly, Verzenio, drugmaker, Eli Lilly's Verzenio, Jeff Legos, Vas, Ludwig Burger, Sriraj Organizations: Novartis, American Society of Clinical Oncology, Oncology, Hematology, Thomson Locations: FRANKFURT, Chicago, U.S, Europe

☆ FDA considers temporary cancer drug imports from unapproved companies to ease U.S. shortage
▼ + stars: | 2023-06-01 | by ( Spencer Kimball | ) www.cnbc.com time to read: +5 min

She is one of hundreds of Ontario cancer patients who received diluted chemotherapy in the last year and who are still undergoing treatment to beat the disease. The FDA in the past has taken similar action to loosen restrictions on imports when faced with drug shortages. At least 14 cancer drugs are currently in short supply across the U.S. Up to 20% of cancer patients rely on platinum-based chemotherapy drugs such as cisplatin and carboplatin for treatment, according to the National Cancer Institute. Some cancer patients could die if the shortages are not quickly resolved, doctors said.

Persons: Dawn Deslippe, Diane Marley, Richard Lautens, Drug Administration –, Julie Gralow, We're, Gralow, —, Abdul Rafeh Naqash, Naqash, Philip Schwieterman, Schwieterman Organizations: Windsor Regional Hospital, Toronto Star, Getty, Drug Administration, CNBC, FDA, U.S, The American Society of Clinical Oncology, World Health, Pharmaceuticals, National Cancer Institute, American Society of Clinical Oncology, Stephenson Cancer Center, University of Oklahoma, University of Kentucky, kiwis Locations: WINDSOR, Ontario, United States, U.S, carboplatin

☆ Link Between Long Telomeres and Long Life Is a Tall Tale, Study Finds
▼ + stars: | 2023-05-04 | by ( Gina Kolata | ) www.nytimes.com time to read: +1 min

Cells have a molecular clock that determines how long they live. The clocks come in the form of caps on the end of chromosomes — the long twisted strings of DNA carrying the cells’ genes. Every time a cell divides, its telomeres get a little shorter, until finally they get so short that the cell dies. While short telomeres do lead to health problems, long telomeres lead to health problems of their own. Far from extending life, long telomeres appear to cause cancer and a blood disorder known as CHIP, a condition that increases the risk of blood cancers and heart disease.

☆ How buzzy weight-loss drugs like Ozempic became the next craze in the hottest part of healthcare
▼ + stars: | 2023-03-14 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Healthcare companies are launching programs left and right to prescribe trendy weight-loss drugs. And Ro, a startup that prescribes and sells products like Viagra and hair-loss pills to consumers, is going all in with a program it launched in January to prescribe the weight-loss drugs to patients online. CalibrateFirst developed to manage type 2 diabetes, GLP-1 medications regulate blood-sugar levels, which can help people curb cravings and feel fuller after eating. The weight-loss market for GLP-1 drugs is relatively new, and not everyone is on board. But for some companies, stepping into prescribing these new weight-loss medications seems to simply be the natural next step for growth.

Search resuls for: "of Oncology"

25 mentions found